Publications by authors named "O V Limankin"
Background: A population-based method for estimating disease burden is commonly used. Nevertheless, these measurements do not entirely capture the comprehensive burden of illness on an individual patient. To address the problem, the Individual Burden of Illness Index (IBI index) Index was created and validated, specifically for major depressive disorder.
View Article and Find Full Text PDFArticle Synopsis
- Recent studies suggest that there may be a connection between lysosomal storage disorders (LSDs) and symptoms of schizophrenia (SCZ), indicating that lysosomal dysfunction could play a role in SCZ development.
- The research involved analyzing lysosomal enzyme activities and alpha-synuclein levels in blood samples from patients with late-onset SCZ and comparing them to patients with Parkinson's disease and healthy controls.
- Significant differences were found, including decreased enzyme activity, higher concentrations of certain lysosphingolipids, and genetic variants linked to LSDs in early-onset SCZ patients, which may contribute to understanding the overlap between these conditions.
Mental health needs of transgender people in Russia remain unmet and stigmatised as in many other countries around the globe. The aim of this study was to assess the stressors and perceived need for mental health care among transgender people in Russia. A structured online survey was conducted in November 2019.
View Article and Find Full Text PDFArticle Synopsis
- - Patients with schizophrenia are more likely to experience depression, indicating possible shared genetic factors or underlying biological mechanisms between the two disorders.
- - A study reviewed literature from the last decade, narrowing down from 459 articles to 45 that focused on genetic predictors of the comorbidity between schizophrenia and depression.
- - Findings suggest that both disorders may share common genetic pathways, emphasizing the need for further genetic research to improve personalized treatment strategies, though challenges remain in fully understanding these connections.
Background: The usage of antipsychotics (APs) is the most robust and scientifically based approach in the treatment of schizophrenia spectrum disorders (SSDs). The efficiency of APs is based on a range of target receptors of the central nervous system (CNS): serotoninergic, dopaminergic, adrenergic, histaminergic and cholinergic. Metabolic disorders are the most severe adverse drug reactions (ADRs) and lead to cardiovascular diseases with a high rate of mortality in patients with SSDs.
View Article and Find Full Text PDF